The Progressive Corporation logo PGR - The Progressive Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 16
HOLD 22
SELL 4
STRONG
SELL
0
| PRICE TARGET: $223.23 DETAILS
HIGH: $247.00
LOW: $198.00
MEDIAN: $228.00
CONSENSUS: $223.23
UPSIDE: 3.88%

Stock News

Beacon Pointe Advisors LLC Buys Shares of 42,790 The Progressive Corporation $PGR

Beacon Pointe Advisors LLC Buys Shares of 42,790 The Progressive Corporation $PGR

Beacon Pointe Advisors LLC purchased a new position in The Progressive Corporation (NYSE: PGR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 42,790 shares of the insurance provider's stock, valued at approximately $9,346,000. Several other institutional

Aug 29, 2026 12:11 AM defenseworld.net
Advisors Capital Management LLC Purchases Shares of 19,623 The Progressive Corporation $PGR

Advisors Capital Management LLC Purchases Shares of 19,623 The Progressive Corporation $PGR

Advisors Capital Management LLC purchased a new position in shares of The Progressive Corporation (NYSE: PGR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,623 shares of the insurance provider's stock, valued at approximately $4,287,000. Several

Aug 21, 2026 11:34 PM defenseworld.net
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of progressive pulmonary fibrosis (PPF). The TETON-PPF study enrolled 754 patients. “The rapid pace of enrollment underscores both the significant unmet need for new treatment options in PPF and the strong interest in nebulized Tyvas.

Aug 17, 2026 03:00 AM businesswire.com

Price Targets